financial guidance

The company saw total revenues of $27 million and product revenues of $16.9 million, as it had estimated in preliminary earnings report last month.

The company beat analyst estimates on the top and bottom lines, and said sales from its diagnostics business rose 13 percent year over year.

Excluding revenues from the sale of MDxHealth's colorectal cancer patents to Exact Sciences, total revenues increased approximately 3 percent for the period.

The firm said that TB screening market growth was impacted by a slowdown in test utilization due to the White House's immigration policies.

The company, which beat analyst estimates on both the top and bottom lines, said Cologuard test volume in Q3 2017 rose 136 percent year over year.

The company said the dramatic increase was driven by a one-time buy-out of patents related to colorectal cancer by Exact Sciences.

The company said revenues from its non-invasive heart transplant rejection test AlloMap rose about 16 percent year over year.

The company missed analyst estimates on its top line, but beat analyst estimates for adjusted earnings per share and raised its adjusted EPS guidance for FY 2017.

The company credited its molecular diagnostics and international businesses as drivers of new growth.